Araştırma Makalesi
BibTex RIS Kaynak Göster

Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals

Yıl 2024, Cilt: 14 Sayı: 2, 642 - 649, 01.06.2024
https://doi.org/10.21597/jist.1402305

Öz

Multiple sclerosis (MS) is a prevalent neurological disease with a global impact on patients' lives. Our study aimed to conduct a bibliometric analysis of research published in the field of pharmacology over the past decade. We retrieved original articles on MS from pharmacology journals in the last ten years through the Scopus database. The collected data underwent analysis using VOSViewer software, examining relationships between studies based on parameters such as citation, authorship, and organizations. In our country-based analysis, the United States emerged with the highest document count, totaling 350, followed by Germany with 210 documents. Claudio Viegas holds the top position with four publications in the last decade. The most prolific organization identified was associated with the Biogen-Cambridge-MA-United States group. However, Chulalongkorn University in Bangkok, Thailand, specifically the Department of Psychiatry, received the most citations. The most cited document was "Therapeutic Advances in Neurological Disorders," while the study with the highest citations was Ferreria-Vieira et al.'s (2016) work published in Current Neuropharmacology. Research efforts on MS treatment are evidently growing, with diverse research groups contributing worldwide. We anticipate that our study will provide valuable guidance to researchers in the field by shedding light on significant research and their interconnections in recent years.

Etik Beyan

The study does not require ethical approval. However, as authors, we declare that we act in accordance with the Publication Ethics.

Destekleyen Kurum

This research received no external funding.

Kaynakça

  • Albuquerque, P. C., Castro, M. J. C., Santos-Gandelman, J., Oliveira, A. C., Peralta, J. M., & Rodrigues, M. L. (2017). Bibliometric indicators of the Zika outbreak. PLoS neglected tropical diseases, 11(1), e0005132.
  • Aleixandre-Benavent, R., Alonso-Arroyo, A., Gonzalez de Dios, J., Vidal-Infer, A., Gonzalez-Munoz, M., & Sempere, A. P. (2015). Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012). Mult Scler, 21(2), 235-245. doi:10.1177/1352458514540357
  • Alryalat, S. A. S., Malkawi, L. W., & Momani, S. M. (2019). Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. JoVE (Journal of Visualized Experiments)(152), e58494.
  • Amin, M., & Hersh, C. M. (2023). Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag, 13(1), 47-70. doi:10.2217/nmt-2021-0058
  • Aria, M., & Cuccurullo, C. (2017). bibliometrix: An R-tool for comprehensive science mapping analysis. Journal of informetrics, 11(4), 959-975.
  • Aykaç, S., & Eliaçık, S. (2022). What are the trends in the treatment of multiple sclerosis in recent studies?–A bibliometric analysis with global productivity during 1980–2021. Multiple Sclerosis and Related Disorders, 68, 104185.
  • Demir, E., Akmeşe, Ö. F., Erbay, H., Taylan-Özkan, A., & Mumcuoğlu, K. Y. (2020). Bibliometric analysis of publications on house dust mites during 1980–2018. Allergologia et immunopathologia, 48(4), 374-383.
  • Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis - a review. Eur J Neurol, 26(1), 27-40. doi:10.1111/ene.13819 Donthu, N., Kumar, S., Mukherjee, D., Pandey, N., & Lim, W. M. (2021). How to conduct a bibliometric analysis: An overview and guidelines. Journal of business research, 133, 285-296.
  • Ellegaard, O., & Wallin, J. A. (2015). The bibliometric analysis of scholarly production: How great is the impact? Scientometrics, 105, 1809-1831.
  • Gelfand J.M. (2014). Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol.
  • Gholamzad, M., Ebtekar, M., Ardestani, M. S., Azimi, M., Mahmodi, Z., Mousavi, M. J., & Aslani, S. (2019). A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res, 68(1), 25-38. doi:10.1007/s00011-018-1185-0
  • Hauser, S. L., & Cree, B. A. C. (2020). Treatment of Multiple Sclerosis: A Review. Am J Med, 133(12), 1380-1390 e1382. doi:10.1016/j.amjmed.2020.05.049
  • Kaba, İ., & Çoşkun, N. (2022). The evolution of COVID-19 publications in pediatrics: a bibliometric analysis with research trends and global productivity: bibliometric analysis of COVID-19 publications in pediatrics. Medical Science and Discovery, 9(8), 421-431.
  • Kosovali, B. D., & Mutlu, N. M. (2023). Global scientific outputs of extracorporeal membrane oxygenation in COVID-19: A bibliometric overview. Perfusion, 38(6), 1153-1164.
  • Lin, J., Zhou, J., & Xu, Y. (2023). Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain, awad070.
  • McGinley MP, Goldschmidt CH, Rae-Grant AD. (2021). Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA, 325(8):765–79. 10.1001/jama.2020.26858
  • Olsson, T., Barcellos, L. F., & Alfredsson, L. (2017). Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology, 13(1), 25-36.
  • Peterson, S., Jalil, A., Beard, K., Kakara, M., & Sriwastava, S. (2022). Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord, 68, 104125. doi:10.1016/j.msard.2022.104125
  • Simkins TJ, Duncan GJ, Bourdette D. (2021). Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications. Curr Neurol Neurosci Rep, 21(6):26. 10.1007/s11910-021-01110-5
  • Thompson A.J., Baranzini S.E., Geurts J., et. al. (2018). Multiple Sclerosis. Lancet Neurol, 391: pp. 1622-1636. Van Eck, N. J., & Waltman, L. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 84(2), 523-538. doi:10.1007/s11192-009-0146-3
  • Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., . . . Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 26(14), 1816-1821. doi:10.1177/1352458520970841
  • Yang, L., Tu, S., Feng, L., Lai, X., & Wang, R. (2021). Bibliometric analysis of multiple sclerosis nursing research based on Web of Science. Ann Palliat Med, 10(7), 7551-7559. doi:10.21037/apm-21-1057
Yıl 2024, Cilt: 14 Sayı: 2, 642 - 649, 01.06.2024
https://doi.org/10.21597/jist.1402305

Öz

Kaynakça

  • Albuquerque, P. C., Castro, M. J. C., Santos-Gandelman, J., Oliveira, A. C., Peralta, J. M., & Rodrigues, M. L. (2017). Bibliometric indicators of the Zika outbreak. PLoS neglected tropical diseases, 11(1), e0005132.
  • Aleixandre-Benavent, R., Alonso-Arroyo, A., Gonzalez de Dios, J., Vidal-Infer, A., Gonzalez-Munoz, M., & Sempere, A. P. (2015). Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012). Mult Scler, 21(2), 235-245. doi:10.1177/1352458514540357
  • Alryalat, S. A. S., Malkawi, L. W., & Momani, S. M. (2019). Comparing bibliometric analysis using PubMed, Scopus, and Web of Science databases. JoVE (Journal of Visualized Experiments)(152), e58494.
  • Amin, M., & Hersh, C. M. (2023). Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag, 13(1), 47-70. doi:10.2217/nmt-2021-0058
  • Aria, M., & Cuccurullo, C. (2017). bibliometrix: An R-tool for comprehensive science mapping analysis. Journal of informetrics, 11(4), 959-975.
  • Aykaç, S., & Eliaçık, S. (2022). What are the trends in the treatment of multiple sclerosis in recent studies?–A bibliometric analysis with global productivity during 1980–2021. Multiple Sclerosis and Related Disorders, 68, 104185.
  • Demir, E., Akmeşe, Ö. F., Erbay, H., Taylan-Özkan, A., & Mumcuoğlu, K. Y. (2020). Bibliometric analysis of publications on house dust mites during 1980–2018. Allergologia et immunopathologia, 48(4), 374-383.
  • Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis - a review. Eur J Neurol, 26(1), 27-40. doi:10.1111/ene.13819 Donthu, N., Kumar, S., Mukherjee, D., Pandey, N., & Lim, W. M. (2021). How to conduct a bibliometric analysis: An overview and guidelines. Journal of business research, 133, 285-296.
  • Ellegaard, O., & Wallin, J. A. (2015). The bibliometric analysis of scholarly production: How great is the impact? Scientometrics, 105, 1809-1831.
  • Gelfand J.M. (2014). Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol.
  • Gholamzad, M., Ebtekar, M., Ardestani, M. S., Azimi, M., Mahmodi, Z., Mousavi, M. J., & Aslani, S. (2019). A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res, 68(1), 25-38. doi:10.1007/s00011-018-1185-0
  • Hauser, S. L., & Cree, B. A. C. (2020). Treatment of Multiple Sclerosis: A Review. Am J Med, 133(12), 1380-1390 e1382. doi:10.1016/j.amjmed.2020.05.049
  • Kaba, İ., & Çoşkun, N. (2022). The evolution of COVID-19 publications in pediatrics: a bibliometric analysis with research trends and global productivity: bibliometric analysis of COVID-19 publications in pediatrics. Medical Science and Discovery, 9(8), 421-431.
  • Kosovali, B. D., & Mutlu, N. M. (2023). Global scientific outputs of extracorporeal membrane oxygenation in COVID-19: A bibliometric overview. Perfusion, 38(6), 1153-1164.
  • Lin, J., Zhou, J., & Xu, Y. (2023). Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain, awad070.
  • McGinley MP, Goldschmidt CH, Rae-Grant AD. (2021). Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA, 325(8):765–79. 10.1001/jama.2020.26858
  • Olsson, T., Barcellos, L. F., & Alfredsson, L. (2017). Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology, 13(1), 25-36.
  • Peterson, S., Jalil, A., Beard, K., Kakara, M., & Sriwastava, S. (2022). Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord, 68, 104125. doi:10.1016/j.msard.2022.104125
  • Simkins TJ, Duncan GJ, Bourdette D. (2021). Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications. Curr Neurol Neurosci Rep, 21(6):26. 10.1007/s11910-021-01110-5
  • Thompson A.J., Baranzini S.E., Geurts J., et. al. (2018). Multiple Sclerosis. Lancet Neurol, 391: pp. 1622-1636. Van Eck, N. J., & Waltman, L. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 84(2), 523-538. doi:10.1007/s11192-009-0146-3
  • Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., . . . Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler, 26(14), 1816-1821. doi:10.1177/1352458520970841
  • Yang, L., Tu, S., Feng, L., Lai, X., & Wang, R. (2021). Bibliometric analysis of multiple sclerosis nursing research based on Web of Science. Ann Palliat Med, 10(7), 7551-7559. doi:10.21037/apm-21-1057
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Yazılım Mühendisliği (Diğer)
Bölüm Biyoloji / Biology
Yazarlar

Mazhar Özkan 0000-0002-8745-2493

Tuğba Nurcan Yüksel 0000-0001-5092-1674

Fatih Tozoğlu 0000-0002-8882-9264

Erken Görünüm Tarihi 28 Mayıs 2024
Yayımlanma Tarihi 1 Haziran 2024
Gönderilme Tarihi 8 Aralık 2023
Kabul Tarihi 1 Şubat 2024
Yayımlandığı Sayı Yıl 2024 Cilt: 14 Sayı: 2

Kaynak Göster

APA Özkan, M., Yüksel, T. N., & Tozoğlu, F. (2024). Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals. Journal of the Institute of Science and Technology, 14(2), 642-649. https://doi.org/10.21597/jist.1402305
AMA Özkan M, Yüksel TN, Tozoğlu F. Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals. Iğdır Üniv. Fen Bil Enst. Der. Haziran 2024;14(2):642-649. doi:10.21597/jist.1402305
Chicago Özkan, Mazhar, Tuğba Nurcan Yüksel, ve Fatih Tozoğlu. “Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals”. Journal of the Institute of Science and Technology 14, sy. 2 (Haziran 2024): 642-49. https://doi.org/10.21597/jist.1402305.
EndNote Özkan M, Yüksel TN, Tozoğlu F (01 Haziran 2024) Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals. Journal of the Institute of Science and Technology 14 2 642–649.
IEEE M. Özkan, T. N. Yüksel, ve F. Tozoğlu, “Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals”, Iğdır Üniv. Fen Bil Enst. Der., c. 14, sy. 2, ss. 642–649, 2024, doi: 10.21597/jist.1402305.
ISNAD Özkan, Mazhar vd. “Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals”. Journal of the Institute of Science and Technology 14/2 (Haziran 2024), 642-649. https://doi.org/10.21597/jist.1402305.
JAMA Özkan M, Yüksel TN, Tozoğlu F. Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals. Iğdır Üniv. Fen Bil Enst. Der. 2024;14:642–649.
MLA Özkan, Mazhar vd. “Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals”. Journal of the Institute of Science and Technology, c. 14, sy. 2, 2024, ss. 642-9, doi:10.21597/jist.1402305.
Vancouver Özkan M, Yüksel TN, Tozoğlu F. Bibliometric Analysis of Multiple Sclerosis Studies in Pharmacology Journals. Iğdır Üniv. Fen Bil Enst. Der. 2024;14(2):642-9.